Cargando…
Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649297/ http://dx.doi.org/10.1186/2051-1426-3-S2-P359 |
| _version_ | 1782401327307948032 |
|---|---|
| author | Wong, Michael KK Morse, Michael A McDermott, David F Clark, Joseph I Kaufman, Howard L Daniels, Gregory A Perritt, Jessica C Hua, Hong Aung, Sandra |
| author_facet | Wong, Michael KK Morse, Michael A McDermott, David F Clark, Joseph I Kaufman, Howard L Daniels, Gregory A Perritt, Jessica C Hua, Hong Aung, Sandra |
| author_sort | Wong, Michael KK |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4649297 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46492972015-11-24 Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 Wong, Michael KK Morse, Michael A McDermott, David F Clark, Joseph I Kaufman, Howard L Daniels, Gregory A Perritt, Jessica C Hua, Hong Aung, Sandra J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4649297/ http://dx.doi.org/10.1186/2051-1426-3-S2-P359 Text en Copyright © 2015 Wong et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Wong, Michael KK Morse, Michael A McDermott, David F Clark, Joseph I Kaufman, Howard L Daniels, Gregory A Perritt, Jessica C Hua, Hong Aung, Sandra Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 |
| title | Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 |
| title_full | Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 |
| title_fullStr | Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 |
| title_full_unstemmed | Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 |
| title_short | Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 |
| title_sort | overall survival of metastatic melanoma patients treated with hd il-2 followed by immune checkpoint blockade of the ctla-4 or the pd-1 pathways: analysis of data on the current use of hd il-2 |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649297/ http://dx.doi.org/10.1186/2051-1426-3-S2-P359 |
| work_keys_str_mv | AT wongmichaelkk overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 AT morsemichaela overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 AT mcdermottdavidf overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 AT clarkjosephi overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 AT kaufmanhowardl overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 AT danielsgregorya overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 AT perrittjessicac overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 AT huahong overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 AT aungsandra overallsurvivalofmetastaticmelanomapatientstreatedwithhdil2followedbyimmunecheckpointblockadeofthectla4orthepd1pathwaysanalysisofdataonthecurrentuseofhdil2 |